In one paragraphArticle in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Philippe DehioDepartment of Biomedicine, Immunobiology, University and University Hospital of Basel, Basel, Switzerland.ORCID 0000-0002-9869-2601 Céline MichardDepartment of Biochemistry, Faculty of Science, University of Geneva, Geneva, Switzerland.ORCID 0000-0001-5215-8510 Anett JandkeDepartment of Biomedicine, Immunobiology, University and University Hospital of Basel, Basel, Switzerland.ORCID 0000-0002-7681-7952 Gunhild UnterstabDepartment of Biomedicine, Immunobiology, University and University Hospital of Basel, Basel, Switzerland.
Lucien FabreDepartment of Biomedicine, Immunobiology, University and University Hospital of Basel, Basel, Switzerland.ORCID 0000-0002-7597-5932 Loïc SauteurMicroscopy Core Facility, Department of Biomedicine, University of Basel, Basel, Switzerland.ORCID 0000-0002-9163-0424 Marc ArtingerInstitute of Cell Biology and Immunology Thurgau, University of Konstanz, Kreuzlingen, Switzerland.ORCID 0009-0006-0487-5930 Daniel F LeglerInstitute of Cell Biology and Immunology Thurgau, University of Konstanz, Kreuzlingen, Switzerland.ORCID 0000-0001-8610-4764 Michael SixtInstitute of Science and Technology Austria, Klosterneuburg, Austria.
Thorsten SchaeferDepartment of Biomedicine, Cancer- and Immunobiology, University of Basel, Basel, Switzerland.ORCID 0000-0003-4867-8374 Matthias P WymannDepartment of Biomedicine, Cancer- and Immunobiology, University of Basel, Basel, Switzerland.
Thierry SoldatiDepartment of Biochemistry, Faculty of Science, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-2056-7931 Matthias MehlingDepartment of Biomedicine, Translational Neuroimmunology, University of Basel and University Hospital Basel, Basel, Switzerland.
Christoph HessDepartment of Biomedicine, Immunobiology, University and University Hospital of Basel, Basel, Switzerland. ch818@cam.ac.uk.ORCID 0000-0003-0364-8825 Funding
Hans Zaeslin Bustany Foundation ZBF Program Award 2025Novartis Stiftung für Medizinisch-Biologische Forschung (Novartis Foundation for Medical-Biological Research) #23A070Novartis Stiftung für Medizinisch-Biologische Forschung (Novartis Foundation for Medical-Biological Research) FZEB-0-180487Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 183980Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 220205Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 225441Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 310030_192677Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 310030B_201277Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) FZEB-0-180487Wellcome Trust 225441
6 · The paper itselfAbstract
Amoeboid cell migration is key to efficient T cell immunity. Spatial polarization of organelles within cells, including endo-lysosomes, is a prerequisite of migration. However, how ultrastructural polarization is linked to the signaling requirements governing T cell migration remains unknown. Here we show that signaling molecules generated by endo-lysosome-localized kinases regulate velocity of amoeboid migration. Specifically, imaging of T cells identifies accumulation of endo-lysosomes decorated with the lipid kinases VPS34-PIKfyve at the uropod of polarized cells. Activity of VPS34 and PIKfyve regulates speed, but not directedness, of migrating T cells. Mechanistically, PI(3,5)P
Indexed as
Cell MovementClass III Phosphatidylinositol 3-KinasesMyosin Type IIPhosphatidylinositol 3-KinasesAnimalsCalciumDictyosteliumHumansLysosomesPhosphatidylinositol PhosphatesSignal TransductionCalciumClass III Phosphatidylinositol 3-KinasesMyosin Type IIPhosphatidylinositol 3-KinasesPhosphatidylinositol Phosphates
Identifiers
PMID42414599
PMCPMC13503823
What OpenQuestion holds
Textmetadata
Read underepoch 390